Provenance Record

Well-structured News piece (841 words, within the 400-1200 News range). Clear Overview / What We Know / What We Don't Know / Analysis scaffold. Technical detail (MRD 10^-6, CRS grading, NINTs, BCMA mechanism, CARTITUDE-1 context) is accurate and appropriately explained without dumbing down. Caveats about single-arm, single-institution, 15.3-month follow-up, and neurologic signal are surfaced honestly.

["Nature Medicine (https://www.nature.com/articles/s41591-026-04365-y) VERIFIED via curl (Nature WebFetch hit a cookie-consent 303; HTML retrieved directly). Title: 'Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial'. Published 20 April 2026. Confirms: 20 treated patients, no induction/bridging, CRS 100% grade 1/2 (no grade 3+), NINTs in 7 patients (4 cranial nerve palsies that fully resolved, 3 with persistent grade 1 symptoms), median follow-up 15.3 months, all 20 reached MRD-negativity at 10^-6 by 2 months and remained MRD-negative, no progression/deaths, BCMA-directed cilta-cel, senior authors include Irene Ghobrial and Omar Nadeem (Dana-Farber), data cutoff 11 Feb 2026. All article claims align with the primary source.","STAT News (https://www.statnews.com/2026/04/20/aacr-2026-car-t-trial-results-carvykti-smoldering-multiple-myeloma/) VERIFIED via WebFetch. Publication date April 20, 2026 confirmed. Confirms AACR presentation in San Diego, 20-patient cohort, 100% MRD-negative response, Darzalex as the only approved therapy for high-risk smoldering myeloma, ~20% progression rate on current standard within 5 years, Dr. Ecaterina Dumbrava's 'cure' / 'early immune interception' framing. Article uses STAT as a secondary framing source and correctly flags the paradigm-shift language as hypothesis, not established outcome.","FDA (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma) VERIFIED via curl through web.archive.org (direct FDA WebFetch blocked by bot-detection 404). Confirms: ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech) approved Feb 28, 2022 for relapsed/refractory multiple myeloma after four or more prior lines of therapy; BCMA-directed CAR T-cell therapy; CARTITUDE-1 ORR 97.9% (95% CI 92.7-99.7). Article's 'approved by the FDA' + 'based on data from CARTITUDE-1 that showed an overall response rate of 97.9 percent' is accurate. Minor nuance: current label is actually for >=1 prior line (post-CARTITUDE-4 expansion), but the original approval and the 97.9% CARTITUDE-1 figure the article cites are both correct as written.","AACR 2026 meeting dates/location (April 17-22, 2026, San Diego Convention Center) cross-verified via aacr.org; matches the article's 'presented at the American Association for Cancer Research Annual Meeting in San Diego'."]

All load-bearing numbers match the Nature Medicine paper: n=20, 100% MRD-neg at 10^-6, median 1 month to MRD-neg, median 15.3 months follow-up, CRS all grade 1/2 (no grade 3+), 7/20 NINTs (4 cranial/facial nerve palsies resolved, 3 persistent grade 1). 'Six patients >18 months without relapse' is consistent with the paper's 16/20 with >6-month follow-up and longest follow-ups. No induction/bridging design is correctly described. 97.9% CARTITUDE-1 ORR matches FDA label. No hallucinated quotes; Dumbrava 'cure' framing is attributed as a STAT-reported researcher hypothesis, not presented as fact.

High-quality submission. Primary source (Nature Medicine CAR-PRISM paper) fully verified; every numeric claim traces back to the paper. Secondary sources (STAT, FDA) are reputable and correctly cited. Framing is appropriately skeptical about durability and generalizability without underselling the result. Ready for publication.